Home
About
Disclaimer
Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Enter Part of Title

Display #

Semaglutide’s Heart Benefits Extend Beyond Weight Loss

Articles

Join the 5K@EASD Virtual Run/Walk for Diabetes Awareness 2024
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
The Potential of GLP-1 Medications for Type 1 Diabetes
Why I Took Medical Courses to Strengthen My Data Skills
Understanding Obesity: Beyond the Scale
Understanding Incretin Receptor Signaling Bias and Its Potential in Treating Obesity and Type 2 Diabetes
Diabetes and Eye Health
The Mounjaro Supply Challenges: Looking Back and Looking Forward
Wegovy: A New Horizon in Cardiovascular Risk Reduction for Obesity
Innovative Weight Loss Medication Shows Promise in Lowering Blood Pressure
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
Eli Lilly's Once-Weekly Insulin Efsitora Alfa Shows Positive Phase 3 Results
The Power of Exercise and Music in Managing Type 2 Diabetes
GLP-1 RAs and Gastroparesis (Stomach Paralysis)
Denmark's AI Supercomputer: A Leap Forward in Tackling Type 2 Diabetes and Obesity
Studies of Cinnamon for Blood Sugar Control: Mixed Results with No Clear Answer
What the 2025 Diabetes Care Updates Mean for You
FDA Issues Alert on Compounded Semaglutide Dosing Errors
Revolutionizing Diabetes and Obesity Care with AI at Novo Nordisk
GLP-1 Drugs and Suicidal Thoughts: A Comprehensive Review by Regulators

News

October 2025

FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment

Contact Us

How many eyes does a typical person have?

Search

Search

You are here:
Home
JCS/T2D - A Diabetes Journey

Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.

Joomla! is Free Software released under the GNU General Public License.